Study enrollment and randomization.

<p>The majority of patients not meeting inclusion criteria had passed away, were free of pain or were no longer being treated in either of the hospitals.</p

Conditioned pain modulation and pain thresholds for pregabalin vs. placebo before and after study treatment.

<p>All values are medians with interquartile ranges. •  =  Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo group.</p

Baseline data for conditioned pain modulation and sum of pain thresholds for pancreatitis patients vs. healthy controls.

<p>All values are medians with interquartile ranges. ‘Control’ is healthy control group and ‘Pancreatitis’ is chronic pancreatitis group. ‘ePDT’ is electric pain detection threshold, ‘ePTT’ is electric pain tolerance threshold, ‘pPDT’ is pressure pain detection threshold, ‘pPPT’ is pressure pain tolerance threshold and ‘CPM’ is conditioned pain modulation.</p

Change and percentage change in conditioned pain modulation and pain thresholds for pregabalin vs. placebo after study treatment.

<p>All values are medians with interquartile ranges. •  =  Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo group.</p

Dermatomes of measurement for quantitative sensory testing.

<p>Quantitative sensory testing was performed on the following sites on the dominant body side (black dots): clavicle (C5 dermatome), sternum (T4 dermatome), pancreatic site (dorsal and ventral T10 dermatome), hip region (L1 dermatome) and knee (L4 dermatome).</p

Sum of pain thresholds for pregabalin vs. placebo before and after treatment.

<p>All values are medians with interquartile ranges. •  =  Measurements after study treatment were significantly higher in the pregabalin group compared to the placebo group.</p

Demographic and clinical characteristics of patients.

<p>All values are medians with interquartile ranges unless mentioned otherwise. Percentages may not total 100 due to rounding.</p>†<p>Weak analgesics were defined as NSAIDS, paracetamol, codeine and tramadol. Strong analgesics were defined as opioid based therapies.</p>‡<p>Alcohol abusing patients were defined as female patients drinking >14 units of alcohol per week or male patients drinking >21 units of alcohol per week.</p><p>‘MEQ’ is morphine equivalents, ‘pregabalin’ is pregabalin study group and ‘placebo’ is placebo study group.</p><p>No statistical differences between groups were observed.</p

Additional file 1: of Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial

Definitions of secondary endpoints. Table S1. Severity of PEP according to Cotton and revised Atlanta criteria. Table S2. Local and systemic complications according to (revised) Atlanta criteria. Table S3. ERCP-related complications (adopted from Cotton). SPIRIT checklist. (DOCX 40 kb